Phase 2
N=12
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Lymphangioleiomyomatosis (LAM)
Bottom Line
View on ClinicalTrials.gov: NCT02484664 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcome: Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 11 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Celecoxib (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Brigham and Women's Hospital
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events as a Measure of Safety and Tolerability |
11 | — |
| SECONDARY FEV1 |
2583 | — |
| SECONDARY Angiomyolipoma Size Measured Volumetrically on MRI |
3 | — |
| SECONDARY St. George's Respiratory Questionnaire |
20.2 | — |
| SECONDARY VEGF-D Serum Levels |
656 | — |
| SECONDARY EBC Prostaglandin Metabolites |
— | — |
| SECONDARY Circ LAM Cell Count |
— | — |
Summary
The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site). The Specific Aims are:
Aim 1: To investigate whether, in LAM patients, celecoxib is safe and well tolerated, and has evidence of clinical benefit.
Aim 2: To investigate the potential value of a novel biomarker of LAM, quantitative measurement of the number of TSC2 mutant LAM cells per ml of blood, to assess disease severity.
Eligibility Criteria
Inclusion Criteria
- Female of age 18 to 69
- Ability to give informed consent
- Definite diagnosis of LAM Typical cystic change on CT scan of the chest plus one of the following i) biopsy or cytology of any tissue demonstrating LAM, ii) angiomyolipoma, chylothorax, clinical or genetic diagnosis of tuberous sclerosis, iii) serum VEGF-D > 800pg/ml
- post-bronchodilator forced expiratory volume in one second ≥ 70% of predicted and DLCO ≥ 70% predicted during baseline visit.
- Women of childbearing potential must agree to use two forms of barrier contraception after screening visit, for the duration of study participation and for 30 days after last dose.
Exclusion Criteria
- History of intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)
- History of current regular use (daily most days of the week) of NSAIDs
- History of use of rapamycin or everolimus
- Uncontrolled intercurrent illness
- Pregnant, breast feeding or planning to become pregnant in the next 2 years
- Significant hematological (platelet count 2 times normal).
- Use of an investigational drug within 30 days of study start
- Inability to attend scheduled clinic visits
- Inability to give informed consent
- Inability to perform spirometry
- Creatinine > 1.0 mg/dl or eGFR 4 cm
- History of vascular disease, including myocardial infarction or stroke
- History of ulcers or GI bleeding
- Allergy to sulfonamides, unless subject has previously used Celocoxib without any adverse reactions.
- Age older than 70
Data sourced from ClinicalTrials.gov (NCT02484664). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.